Lipid and Inflammatory Cardiovascular Risk Worsens Over 3 Years in Youth With Type 2 Diabetes
Author:
- TODAY Study GroupTGTODAY Study Group
Open Access
- 15 May 2013
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 36 (6) , 1758-1764
Abstract
OBJECTIVE: Type 2 diabetes increases cardiovascular risk. We examined lipid profiles and inflammatory markers in 699 youth with recent-onset type 2 diabetes in the TODAY clinical trial and compared changes across treatment groups: metformin alone (M), metformin plus rosiglitazone (M+R), and metformin plus intensive lifestyle program (M+L). RESEARCH DESIGN AND METHODS: Multiethnic youth with type 2 diabetes received M, M+R, or M+L. Statin drugs were begun for LDL cholesterol (LDL) ≥130 mg/dL or triglycerides ≥300 mg/dL. Lipids, apolipoprotein B (apoB), LDL particle size, high-sensitivity c-reactive protein (hsCRP), homocysteine, plasminogen activator inhibitor-1 (PAI-1), and HbA1c were measured over 36 months or until loss of glycemic control. RESULTS: LDL, apoB, triglycerides, and non-HDL cholesterol (HDL) rose over 12 months and then stabilized over the next 24 months. Participants with LDL ≥130 mg/dL or using LDL-lowering therapy increased from 4.5 to 10.7% over 36 months, while 55.9% remained at LDL goal (<100 mg/dL) over that time. Treatment group did not impact LDL, apoB, or non-HDL. Small dense LDL (particle size, ≤0.263 relative flotation rate) was most common in M. Triglycerides were lower in M+L than M, and M+L attenuated the negative effect of hyperglycemia on triglycerides and HDL in females. hsCRP, PAI-1, and homocysteine increased over time. However, hsCRP was lower in M+R compared with M or M+L. CONCLUSIONS: Dyslipidemia and chronic inflammation were common in youth with type 2 diabetes and worsened over time. Diabetes treatment, despite some treatment group differences in lipid and inflammatory marker change over time, is generally inadequate to control this worsening risk.Keywords
This publication has 23 references indexed in Scilit:
- A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 DiabetesNew England Journal of Medicine, 2012
- Racial/ethnic discrepancies in the metabolic syndrome begin in childhood and persist after adjustment for environmental factorsNutrition, Metabolism and Cardiovascular Diseases, 2012
- Depressive Symptoms and Quality of Life in Adolescents With Type 2 DiabetesDiabetes Care, 2011
- Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 DiabetesDiabetes Care, 2011
- Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY studyInternational Journal of Obesity, 2009
- Insulin Resistance in Adolescents with Type 2 Diabetes Is Associated with Impaired Exercise CapacityThe Journal of Clinical Endocrinology & Metabolism, 2009
- Development of a Diabetes Education Program for Youth With Type 2 DiabetesThe Diabetes Educator, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetesPediatric Diabetes, 2007
- Relation of Glycohemoglobin and Adiposity to Atherosclerosis in YouthArteriosclerosis, Thrombosis, and Vascular Biology, 1995